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OBJECTIVES Our aim was to determine whether sildenafil citrate (Viagra) unfavorably alters coronary
perfusion in canine models of coronary artery stenosis.
BACKGROUND Concern has been raised that sildenafil may exacerbate ischemia in patients with coronary
artery disease. However, the effects of sildenafil on coronary perfusion are largely unexplored.
METHODS Using anesthetized dogs, a micromanometer constrictor was applied to either an intact
coronary artery (model of stable hypoperfusion: Protocol 1) or a site of arterial injury (model
of recurrent platelet-mediated thrombosis: Protocol 2). After monitoring coronary flow for
1 h, dogs received two escalating, clinically relevant doses of sildenafil or placebo. Perfusion
was assessed during the initial hour pretreatment, for 1 h following dose 1 and 1 h following
dose 2 by measuring the area of the flow-time profile, normalized to baseline flow 3 60 min.
Interaction between sildenafil and adenosine-mediated inhibition of platelet aggregation was
evaluated by in vitro platelet aggregometry (Protocol 3).
RESULTS In Protocol 1, flow-time area was maintained at 50% to 60% of baseline in both placebo- and
sildenafil-treated groups. In Protocol 2, controls exhibited an expected modest, temporal
adenosine-mediated improvement in flow-time area (from 40 6 5% to 61 6 7%; p , .05)
while in contrast, perfusion in sildenafil-treated dogs remained unchanged (37 6 6% vs. 33%
to 35% before vs. after treatment). In vitro aggregometry confirmed that sildenafil rendered
platelets refractory to the inhibitory effects of adenosine receptor stimulation.
CONCLUSIONS Sildenafil did not exacerbate ischemia in canine models of coronary stenosis. However, in the
setting of recurrent thrombosis, sildenafil-treated dogs were apparently unresponsive to the
platelet inhibitory effects of endogenous adenosine. (J Am Coll Cardiol 2001;37:286–92) ©
2001 by the American College of Cardiology
Since its release in 1998, sildenafil citrate (Viagra) has
gained widespread popularity as the first pharmacologic
agent prescribed for the treatment of erectile dysfunction
(1,2). Although Viagra is clearly contraindicated in patients
concurrently using nitrates, guidelines issued by the Amer-
ican Heart Association and American College of Cardiol-
ogy have suggested caution in administering Viagra to all
patients with coronary artery disease and active ischemia as
the drug may, in theory, compromise coronary perfusion by
causing coronary vasodilation and initiating “coronary steal,”
and/or as a secondary consequence of hypotension due to
systemic vasodilation (1). Indeed, although most safety
profiles have been benign (2–6), one preliminary study
suggests that Viagra per se may have adverse cardiovascular
consequences (7).
Despite these potential concerns, the effects of sildenafil
on coronary and myocardial tissue perfusion in the setting of
coronary artery stenosis remain largely unexplored (5,8).
Our aim was to determine, using the anesthetized dog,
whether sildenafil unfavorably alters coronary perfusion and
patency in two clinically relevant models: 1) in the setting of
stable hypoperfusion through a narrowed but intact coro-
nary artery (mimicking clinical instances of “hibernating”
myocardium); and 2) in a model of unstable angina, char-
acterized by recurrent platelet-mediated thrombosis and
variable coronary blood flow through a damaged and ste-
notic coronary artery. We found no evidence that sildenafil
exacerbated ischemia in either model. However, in the
model of recurrent thrombosis, sildenafil appeared to block
the modest, temporal, adenosine-mediated improvement in
coronary patency typically observed in placebo-control ani-
mals (9). This unexpected finding was supported by in vitro
platelet aggregometry: although coronary perfusion was not
worsened with sildenafil treatment, our preliminary findings
suggest the agent may render platelets refractory to the
well-described platelet inhibitory effects of adenosine recep-
tor stimulation.
METHODS
This study conforms to the Position of the American Heart
Association on Research Animal Use.
Surgical preparation. Twenty-six purpose-bred dogs
(14–22 kg) were anesthetized with sodium pentobarbital
(30 mg/kg IV), intubated and ventilated with room air.
After cannulating the left carotid artery (for measurement of
hemodynamics) and jugular vein (for drug administration),
the heart was exposed through a left thoracotomy. Two
adjacent segments of the mid-LAD (left anterior descend-
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ing coronary artery) were isolated: the first served as the site
of later coronary stenosis while the second was instrumented
with a Doppler flow probe for continuous measurement of
mean CBF. In addition, in dogs enrolled in Protocol 1, a
cannula was positioned in the left atrial appendage for later
injection of radiolabeled microspheres (141Ce or 103Ru)
for measurement of regional myocardial blood flow
(RMBF). Arterial pressure and coronary blood flow
(CBF) were continuously recorded on a chart recorder.
Protocol 1: Coronary Artery Stenosis 3 Stable Coronary
Flow
Coronary perfusion in the setting of coronary artery stenosis
was assessed in 12 dogs. After 10 min of stabilization and
baseline measurement of hemodynamics and CBF, a mico-
manometer constrictor was positioned around the LAD and
tightened such that mean CBF was reduced to ;50% of
baseline. This application of a stenosis on an undamaged
artery results in maintenance of stable coronary hypoperfu-
sion, and represents a model of “short-term myocardial
hibernation” (10,11).
CBF and hemodynamics were monitored for 1 h after
placement of the stenosis and, at 45 min post-stenosis,
RMBF was assessed. After this 1-h pretreatment period,
each dog was randomly assigned to receive either an
escalating dose of sildenafil citrate (Viagra; Pfizer Inc., New
York, New York) or placebo (n 5 6 per group). Specifically,
Viagra tablets were crushed and 0.7 mg/kg sildenafil was
dissolved in 10 ml saline (12) and given IV over 2 min (dose
1), approximating, on a mg/kg basis, the clinical dose of
50 mg administered to a 70 kg patient. At 2 h post-stenosis,
the drug-treated cohort received a second, identical
0.7 mg/kg dose. As the plasma half-life of sildenafil is ;4 h
(1,4), the cumulative dose during the final hour of observa-
tion was 1.4 mg/kg (;100 mg per 70 kg patient). Controls
received two matched 10 ml doses of saline. CBF and
hemodynamics were monitored in all dogs throughout the
2 h following treatment and, at 45 min after dose 2, a
second measurement of RMBF was obtained. At 3 h
post-stenosis, all dogs were euthanized under deep anesthe-
sia by intracardiac injection of KCl, and the hearts were
excised and stored in formalin.
Endpoints and Analysis. Heart rate, mean arterial pres-
sure and CBF were quantified at baseline, immediately upon
application of the stenosis, at 30 and 60 min post-stenosis
(pretreatment), during IV administration of each dose at the
time (typically within 1 min) at which the maximal hemo-
dynamic response to sildenafil was observed and at 30 and
60 min after each dose.
Coronary perfusion throughout the 1-h pretreatment
period, the 1 h following dose 1, and the 1 h following dose
2 was assessed by measuring the area of the flow-time profile
(i.e., by computerized planimetry of the chart recording).
Flow-time area in each hourly interval was then normalized
for each dog to its baseline CBF 3 60 min (9,13).
RMBF was measured in subendo- and subepicardial tissue
blocks cut from the center of the stenotic LAD bed and
from the remote, normally perfused circumflex bed using
routine methods (10).
Protocol 2: Coronary Artery Injury 1 Stenosis 3
Cyclic Variations in Coronary Blood Flow (CFVs)
Fourteen dogs were enrolled to assess coronary perfusion in
the setting of coronary artery injury 1 stenosis. Baseline
measurement of CBF and hemodynamics were obtained as
described for Protocol 1, and in addition, 4.5 ml of venous
blood was drawn for assessment of in vitro platelet aggre-
gation. The isolated LAD segment was then compressed
with a wax-coated hemostat to induce arterial injury (9,13)
and a micromanometer constrictor was positioned at the site
of injury and tightened such that CBF was reduced to
;50% of its baseline value. This scenario of coronary artery
injury 1 stenosis triggers the rapid (within ,5 min)
development of CFVs caused by the repeated spontaneous
formation and dislodgement of platelet-rich thrombi, and
mimics the repeated ischemia seen in instances of unstable
angina (9,13,14).
CBF and hemodynamics were recorded for 1 h after
injury 1 stenosis. Dogs were then randomized to receive
sildenafil (n 5 7) or saline (n 5 7) as described for Protocol
1 and were monitored for 2 h following treatment. Addi-
tional blood samples were drawn for measurement of in
vitro platelet aggregation at 30 min after each dose. At 3 h
post-stenosis, the animals were euthanized under deep
anesthesia as detailed in Protocol 1.
Endpoints and Analysis. HEART RATE AND MEAN ARTE-
RIAL PRESSURE were measured as described in Protocol 1.
CBF was assessed at baseline and immediately following
injury 1 stenosis, before the onset of CFVs.
IN VITRO PLATELET AGGREGATION was assessed by whole
blood impedance aggregometry (13,15). Briefly, each 4.5 ml
blood sample was immediately mixed with 0.5 ml of 3.8%
sodium citrate. Blood aliquots (0.5 ml) were diluted with an
equal volume of sterile 0.9% saline, maintained at 37°C, and
the increase in impedance (in ohms: an index of platelet
aggregation) at 10 min following the addition of 10 mg
collagen (a dose that elicits maximal aggregation in our
canine model [13,15]) was recorded.
Abbreviations and Acronyms
cAMP 5 adenosine 39,59-cyclic monophosphate
cGMP 5 guanosine 39,59-cyclic monophosphate
CBF 5 coronary blood flow
CFVs 5 cyclic variations in coronary blood flow
LAD 5 left anterior descending coronary artery
NO 5 nitric oxide
PDE 5 5 phosphodiesterase 5
RMBF 5 regional myocardial blood flow
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CFVS were analyzed by measuring both their frequency and
mean nadir during each 1-h interval. A CFV was defined as
a slow decrease followed by an abrupt (within 20 s) increase
in CBF, with an amplitude $50% of the post-stenotic CBF
value (9,13).
CORONARY PATENCY during each hourly interval was as-
sessed by measuring % flow-time area (area of the flow-time
profile normalized to baseline flow 3 60 min, as described
in Protocol 1), and the duration (in minutes) of total
thrombotic occlusion (CBF 5 0) (9).
Protocol 3: Effect of Adenosine A2 Receptor Agonist on In
Vitro Platelet Aggregation
To obtain insight as to whether the modest difference in
coronary patency seen in sildenafil-treated dogs in Protocol
2 may be due to a difference in the response of the platelets
to adenosine, we used whole-blood impedance aggregom-
etry to assess the effects of sildenafil, the adenosine A2
receptor agonist CGS 21680 (16), and sildenafil 1 CGS on
in vitro platelet aggregation.
The effects of exogenous sildenafil were evaluated in
baseline blood samples obtained from one dog. Either
sildenafil (14 mg per 1 ml blood, approximating the total
cumulative in vivo dose of 1.4 mg/kg), CGS 21680 (final
concentration of 10 mM), sildenafil 1 CGS, or a compa-
rable volume of saline (control: no drug) were added to
blood aliquots prepared as described for Protocol 2. Silde-
nafil and CGS were added to the aliquots at 30 min and
10 min, respectively, before initiating platelet aggregation
with collagen (10 mg).
To assess the effects of in vivo sildenafil treatment,
baseline blood samples were drawn from four dogs—two
control and two sildenafil-treated—entered into Protocol 1.
Paired aliquots were prepared, with CGS 21680 (10 mM)
added to one tube and saline added to the second. Aggre-
gation in response to collagen was measured for each
sample, and the % difference in response (i.e., [aggregation
in the CGS-treated sample 2 aggregation in the “no drug”
sample]/[aggregation in the “no drug” sample] 3 100%) was
determined. At 30 min following dose 2, additional blood
samples were obtained from all four dogs and assessment of
platelet aggregation in paired vehicle- and CGS-treated
samples was repeated.
Statistical analysis. For Protocols 1 and 2, all variables
were compared using two-factor analysis of variance (for
group and time) with replication followed by Newman–
Keuls post-hoc test. A p value of ,0.05 was considered
statistically significant. For Protocol 3, qualitative compar-
isons of platelet aggregation were made among control,
sildenafil-, CGS- and sildenafil 1 CGS-treated aliquots.
All results are presented as mean 6 SEM (standard error of
the mean).
RESULTS
Protocol 1: Coronary Artery Stenosis 3 Stable Coronary
Flow
Hemodynamics. Heart rate was not altered by sildenafil
and did not differ between groups (Table 1). Sildenafil did,
however, trigger an acute reduction in mean arterial pressure
(1,4): for dose 1, the maximum decrease, seen 38 6 6 s into
the 2-min IV administration of sildenafil, was 28 6
3 mm Hg while, for dose 2, a maximum decrease in pressure
of 24 6 4 mm Hg was observed at 39 6 6 s into treatment.
This effect was transient, with arterial pressure typically
recovering to pretreatment values within 5 min and no
differences seen between groups at 30 and 60 min following
either dose.
Severity of coronary stenosis. Coronary blood flow aver-
aged 14 –15 ml/min at baseline and was reduced to
7–8 ml/min upon application of the stenosis (p 5 ns
between groups; Table 1).
Coronary perfusion. CBF was depressed versus baseline,
but did not differ versus the stenotic value, in all dogs during
the 3 h of observation (p 5 ns between groups; Table 1).
Similarly, flow-time area, the overall index of vessel patency,
averaged 50% to 60% of baseline throughout the protocol in
both control and drug-treated cohorts (p 5 ns; Fig. 1A).
Regional myocardial blood flow. RMBF in the subendo-
and subepicardial halves of the stenotic LAD bed was
similar in both groups before randomization and was not
altered by either sildenafil or placebo (Fig. 1B). In addition,
RMBF in the normally perfused circumflex territory did not
differ between groups either before treatment or after dose 2
(data not shown).
Protocol 2: Coronary Artery Injury 1 Stenosis 3 CFVs
Hemodynamics. There were no group differences in heart
rate at any time during the protocol (Table 1). Mean arterial
pressure, was, by chance, higher at baseline in dogs later
randomized to receive sildenafil; however, the drug-treated
group exhibited the same transient reductions in mean
pressure as described for Protocol 1.
Severity of coronary stenosis. Baseline CBF averaged
12 ml/min and was reduced to 5.5 ml/min in both groups
upon application of the stenosis (p 5 ns; Table 1).
In vitro platelet aggregation. Maximal platelet aggrega-
tion in response to 10 mg collagen was 12–14 ohms at
baseline and was not altered by treatment with sildenafil or
vehicle (Fig. 2A).
CFVs. All dogs exhibited 6–8 CFVs during the initial
hour following injury 1 stenosis, with no change in fre-
quency following administration of sildenafil or saline (data
not shown).
The mean nadir of the CFVs averaged 1.7–2.0 ml/min
before randomization and 1.4–2.7 ml/min during the final
hour of treatment (p 5 ns between groups or over time; data
not shown).
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Coronary patency. The mean duration of total thrombotic
occlusion was 16–20 min during the initial hour of obser-
vation and 11–13 min following dose 2 (p 5 ns between
groups or over time; data not shown).
Flow-time area, the overall index of vessel patency, was
comparable in both groups before treatment, averaging
40 6 5% and 37 6 6% of baseline in dogs later randomized
to receive placebo and sildenafil (Fig. 2B). In control
animals, flow-time area showed the expected modest in-
crease over time (9), to a mean of 61 6 7% of baseline
during the final hour of observation (p , 0.05 vs. pretreat-
ment). In contrast, in sildenafil-treated dogs, flow-time area
remained unchanged at 33% to 35% following administra-
tion of dose 1 and dose 2 (p 5 ns vs. pretreatment; p , 0.05
vs. control following dose 2; Fig. 2B).
Protocol 3: Effect of Adenosine A2 Receptor Agonist on In
Vitro Platelet Aggregation
As expected, exogenous addition of sildenafil to blood
aliquots had no effect on in vitro platelet aggregation (17)
(Fig. 3A), whereas adenosine A2 receptor stimulation with
CGS 21680 elicited a ;25% reduction in platelet aggrega-
Table 1. Hemodynamics
Baseline Stenosis
PreTreat Dose 1 Dose 2
30 min 1 h Max 30 min 1 h Max 30 min 1 h
Protocol 1: Coronary Artery Stenosis 3 Stable Coronary Flow
Heart rate (beats/min)
Control 165 6 8 167 6 8 170 6 8 171 6 10 172 6 10 173 6 8 172 6 7 171 6 8 169 6 7 176 6 5
Sildenafil 146 6 4 150 6 5 156 6 9 159 6 9 157 6 11 161 6 12 161 6 9 157 6 14 162 6 20 164 6 13
Mean arterial pressure
(mm Hg)
Control 99 6 6 103 6 7 113 6 5 119 6 7† 118 6 6† 121 6 6† 122 6 6† 120 6 6† 124 6 6† 125 6 5†
Sildenafil 108 6 5 118 6 5 116 6 5 117 6 4 87 6 5*†‡ 111 6 3 114 6 8 91 6 7*†‡ 113 6 8 117 6 8
Mean coronary blood
flow (ml/min)
Control 14.9 6 2.4 7.8 6 1.3† 8.9 6 1.7† 8.9 6 2.1† 10.0 6 2.0† 10.6 6 2.2† 8.4 6 1.7† 7.8 6 1.4† 9.0 6 1.9† 9.7 6 2.5†
Sildenafil 14.4 6 2.0 7.4 6 1.0† 7.6 6 0.6† 8.7 6 1.3† 6.5 6 1.4† 8.4 6 1.5† 7.9 6 1.4† 6.6 6 1.8† 7.6 6 1.5† 8.7 6 1.8†
Protocol 2: Coronary Artery Injury 1 Stenosis 3 CFVs
Heart rate (beats/min):
Control 140 6 4 143 6 4 149 6 5 157 6 5† 154 6 5† 159 6 5† 164 6 5† 161 6 6† 164 6 6† 167 6 6†
Sildenafil 147 6 9 151 6 8 155 6 8 160 6 9 167 6 11† 160 6 9 160 6 8 166 6 12† 163 6 12† 163 6 8†
Mean arterial pressure
(mm Hg)
Control 95 6 7 95 6 7 104 6 6 111 6 6 109 6 6 109 6 6 118 6 7† 116 6 7† 120 6 6† 122 6 7†
Sildenafil 117 6 9* 122 6 10* 127 6 9* 131 6 10*† 99 6 8†‡ 129 6 9* 125 6 8 107 6 9‡ 120 6 6 123 6 7
Mean coronary blood
flow (ml/min)
Control 11.9 6 1.8 5.6 6 0.9† Onset of CFVs: discrete measurements of coronary blood flow not applicable
Sildenafil 11.6 6 1.2 5.4 6 0.9†
CFVs 5 cyclic variations in coronary blood flow; Max 5 maximum response to sildenafil/vehicle.
*p , 0.05 vs. control; †p , 0.05 vs. baseline; ‡p , 0.05 vs. preceding measurement.
Figure 1. Results (group means 6 SEM) for Protocol 1: coronary artery
stenosis 3 stable coronary flow. (A) % Flow-time area and (B) Regional
myocardial blood flow (RMBF) in endocardial (Endo) and epicardial (Epi)
segments of the stenotic left anterior descending coronary artery bed for
control and sildenafil-treated dogs. Black bars indicate controls; white
bars indicate sildenafil. PreTreat 5 data obtained during the initial hour
before randomization and treatment.
Figure 2. Results (group means 6 SEM) for Protocol 2: coronary artery
injury 1 stenosis3 cyclic variations in coronary flow (CFVs). (A) In vitro
platelet aggregation (i.e., maximum impedance in response to 10 mg
collagen), and (B) % Flow-time area for control and sildenafil-treated dogs.
Black bars indicate controls; white bars indicate sildenafil. PreTreat 5
data obtained during the initial hour before randomization and treatment.
* p , 0.05 vs. control; † p , 0.05 vs. PreTreat.
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tion (18) (Fig. 3). However, in samples exposed to both
sildenafil and CGS, the platelet inhibitory effects of CGS
21680 were not manifest. This apparent refractoriness to A2
receptor stimulation was seen both with exogenous addition
of sildenafil to blood aliquots (Fig. 3A) and with in vivo
sildenafil treatment (Fig. 3B).
DISCUSSION
Our results demonstrate that sildenafil does not exacerbate
myocardial ischemia in canine models of short-term “hiber-
nation” and unstable angina. However, in the model of
recurrent platelet-mediated thrombosis, sildenafil did abro-
gate the modest, temporal adenosine-mediated improve-
ment in coronary patency seen in placebo controls. This
latter observation, together with our results obtained using
in vitro platelet aggregometry, suggests that sildenafil-
treated dogs may be unresponsive to the platelet inhibitory
effects of adenosine receptor stimulation.
Sildenafil in models of stable coronary hypoperfusion.
Sildenafil elicits smooth muscle relaxation and vasodilation
by selective inhibition of guanosine 39,59-cyclic monophos-
phate (cGMP)-specific phosphodiesterase 5 (PDE 5),
thereby amplifying cGMP-mediated signaling initiated by
the release of nitric oxide (NO). Indeed, inhibition of PDE
5, present in high concentrations in the corpus cavernosum,
represents the mechanism by which sildenafil facilitates
penile erection, and amplification of cGMP-mediated sig-
naling by sildenafil is responsible for its profound and
deleterious potentiation of the hypotensive effect of nitrates
(1,2).
Sildenafil may also trigger coronary vasodilation: PDE 5
is present in coronary vascular smooth muscle (17) and,
under conditions of reduced coronary blood flow, NO (the
substrate for cGMP-mediated signaling) is liberated from
ischemic myocardium (19). Although vasodilation in the
vascular bed distal to a coronary stenosis may improve blood
flow to the hypoperfused territory, sildenafil could, alterna-
tively, exacerbate ischemia due to either coronary steal or as
a result of hypotension due to systemic vasodilation. How-
ever, we found no deterioration in coronary perfusion with
sildenafil in the setting of stable hypoperfusion. These data
are consistent with two reports showing no decrease in
coronary blood flow with sildenafil in men with coronary
artery disease (5) or in conscious dogs with coronary artery
stenosis subjected to treadmill exercise (8). Our current
study extends these observations and demonstrates that
sildenafil is also benign with respect to myocardial tissue
perfusion (RMBF) in this model of short-term “hiberna-
tion.”
Sildenafil in the setting of coronary artery injury 1
stenosis and CFVs. Protocol 1 revealed that sildenafil does
not cause a vasodilatory-induced reduction in coronary
perfusion distal to a narrowed but intact coronary artery.
However, many patients with coronary disease exhibit
arterial damage at the site of coronary stenosis (14); this
serves as a powerful substrate for the activation, adhesion
and aggregation of platelets and initiates the well-
characterized development of CFVs caused by recurrent
spontaneous formation/dislodgement of platelet-rich
thrombi at the site of injury 1 stenosis (9,13,14). Nitric
oxide and upregulation of cGMP-mediated signaling, in
addition to initiating vasodilation, is also well recognized as
a potent inhibitor of platelet aggregation (13,20). Platelets
are rich in PDE 5 (19,21), and in fact PDE 5 inhibitors
have been proposed as a novel class of antiplatelet drugs
(21). Thus, in contrast to the potential deleterious effects of
PDE 5-mediated vasodilation, these data suggest that
sildenafil may, in theory, attenuate the development of
CFVs—and thus improve patency—in the setting of coro-
nary artery injury 1 stenosis by cGMP-mediated inhibition
of platelet aggregation.
As anticipated from our previous studies (9), dogs in the
control group of Protocol 2 exhibited a modest temporal
improvement in coronary patency during the 3-h protocol,
apparently triggered by release of adenosine from ischemic/
reperfused myocardium during early episodes of spontane-
ous thrombotic occlusion/reperfusion and resultant partial
inhibition of platelet aggregation via stimulation of platelet
adenosine A2 receptors (9,22,23). However, as further
Figure 3. Whole-blood impedance aggregometry: Protocol 3. (A) Original
recordings of in vitro platelet aggregation (i.e., increase in impedance) in
blood aliquots exogenously treated with sildenafil, the adenosine A2 agonist
CGS 21680, sildenafil 1 CGS 21680, and no drug (control). Arrows
indicate addition of collagen (10 mg); bar 5 2 min. (B) % Change in
impedance (mean 6 SEM) seen in CGS 21680-treated aliquots versus
paired “no drug” samples. Data were obtained at baseline and after dose 2
in two vehicle-treated and two sildenafil-treated dogs. Black bars indicate
controls; white bars indicate sildenafil.
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expected, this endogenous release of adenosine is not
sufficient to prevent platelet aggregation (9): this is sup-
ported by the lack of temporal variation in in vitro aggre-
gation in response to a maximal stimulus (10 mg collagen)
between the final versus first hour of the protocol.
Sildenafil did not attenuate maximal in vitro platelet
aggregation; this is consistent with previous observations in
which sildenafil was added exogenously to platelet-rich
plasma (17) and with results in blood samples obtained from
Viagra-treated men (5). Moreover, in contrast to our
premise, sildenafil did not improve in vivo coronary patency
when compared with data obtained before treatment, or
versus time-matched placebo controls. In fact, although
patency did not deteriorate with sildenafil treatment, the
typical modest improvement in % flow-time area over time
was not manifest in sildenafil-treated dogs.
Confounding effect of sildenafil on in vitro, adenosine
A2-mediated inhibition of platelet aggregation. The lack
of a temporal improvement in vessel patency in the
sildenafil-treated cohort prompted us to investigate the
possibility that sildenafil may render platelets refractory to
the inhibitory effects of adenosine. Support for this concept
was obtained in Protocol 3, in which we found that
sildenafil appeared to abrogate the ability of CGS 21680 to
attenuate in vitro platelet aggregation. However, the mech-
anisms by which sildenafil (which presumably augments
platelet cGMP content via inhibition of PDE 5 [17,21])
might block A2-mediated inhibition of platelet aggregation
(achieved by stimulation of adenylate cyclase and upregula-
tion of adenosine 39,59-cyclic monophosphate [cAMP]
[21]) are unclear. There is evidence of “cross-talk” between
cGMP- and cAMP-mediated signaling (21,24) but, con-
trary to the implications of our study, sildenafil potentiated
(rather than blocked) cAMP production in an isolated
cardiac muscle preparation (24). Further in vitro studies,
focusing on possible interactions among sildenafil, cGMP-
and cAMP-mediated signaling in platelets are needed to
resolve this issue.
Summary and future directions. Sildenafil did not worsen
coronary perfusion or exacerbate myocardial ischemia in our
experimental models of coronary artery stenosis. However,
in the setting of recurrent platelet-mediated thrombosis,
sildenafil did exert an unexpected and apparently confound-
ing effect on adenosine-mediated inhibition of platelet
aggregation.
These results were obtained in short-term experiments
employing acute canine models and, although the data are
consistent with the current guidelines recommending cau-
tion in administering Viagra to patients with active ischemia
(1), confirmation of the clinical relevance of our observa-
tions will require further study. Second, the mechanism(s)
by which sildenafil alters the response of platelets to
adenosine remains to be elucidated. Finally, the question of
whether Viagra may attenuate the efficacy of other puriner-
gic anti-platelet agents (i.e., ticlopidine, clopidogrel or
dipyridamole) has, to date, not been explored (1) and may,
on the basis of our current results, warrant future investi-
gation.
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